These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 19492468)
41. Common CCR 5 polymorphism in stroke: the CCR 5 delta32 polymorphism differentiates cardioembolism from other aetiologies of ischaemic cerebrovascular diseases. Kostulas N; Markaki I; Kostulas V; Hillert J; Kostulas K Scand J Immunol; 2009 Nov; 70(5):475-80. PubMed ID: 19874552 [TBL] [Abstract][Full Text] [Related]
42. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals. Song IU; Kim JS; Chung SW; Lee KS Eur Neurol; 2009; 62(2):99-104. PubMed ID: 19521085 [TBL] [Abstract][Full Text] [Related]
43. Quantitative C reactive protein levels and acute myocardial infarction complications in a Hispanic population: an observational analytical pilot study. Rentas E; Pérez Arzola M; Bredy R Bol Asoc Med P R; 2006; 98(4):284-9. PubMed ID: 19610570 [TBL] [Abstract][Full Text] [Related]
45. Risk of ischemic heart and ischemic cerebrovascular disease is not increased in S, Z, and 11478A alpha1-antitrypsin carriers of the Copenhagen City Heart Study. Dahl M; Tybjaerg-Hansen A; Nordestgaard BG Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):e55; author reply e55. PubMed ID: 14617620 [No Abstract] [Full Text] [Related]
46. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Razzouk L; Muntner P; Bansilal S; Kini AS; Aneja A; Mozes J; Ivan O; Jakkula M; Sharma S; Farkouh ME Am Heart J; 2009 Aug; 158(2):277-83. PubMed ID: 19619706 [TBL] [Abstract][Full Text] [Related]
47. Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon. Di Napoli M; Papa F Expert Rev Neurother; 2004 Jul; 4(4):613-22. PubMed ID: 15853580 [TBL] [Abstract][Full Text] [Related]
48. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Hornstrup LS; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1441-7. PubMed ID: 23580146 [TBL] [Abstract][Full Text] [Related]
49. [Clinical differences between heart failure versus ischemic patients]. Pinelli M; Bindi M; Moroni F; Rosada J; Castiglioni M Recenti Prog Med; 2007; 98(7-8):378-83. PubMed ID: 17685185 [TBL] [Abstract][Full Text] [Related]
50. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. Bagheri N; Taziki O; Falaknazi K Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):789-93. PubMed ID: 19736474 [TBL] [Abstract][Full Text] [Related]
51. [C-reactive protein, risk of and survival after cancer--secondary publication]. Allin KH; Bojesen SE; Nordestgaard BG Ugeskr Laeger; 2009 Nov; 171(48):3510-3. PubMed ID: 19953727 [TBL] [Abstract][Full Text] [Related]
52. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases. Hamer M; Chida Y; Stamatakis E Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608 [TBL] [Abstract][Full Text] [Related]
53. C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology? Di Napoli M; Papa F Circulation; 2005 Aug; 112(6):781-5. PubMed ID: 16087807 [No Abstract] [Full Text] [Related]
54. Inflammation in the development of lung cancer: epidemiological evidence. Engels EA Expert Rev Anticancer Ther; 2008 Apr; 8(4):605-15. PubMed ID: 18402527 [TBL] [Abstract][Full Text] [Related]